AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2669718
Drug: Pre-operative antiseptic
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative antiseptic preparation
Trial: 770363
Drug: Pimozide at
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimozide at doses of 2 mg/day
Trial: 770363
Drug: Diazepam at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam at doses of 3 x 5 mg
Trial: 28385672
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy with shocks
Trial: 28385672
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy with ATP
Trial: 24101169
Drug: Sentinel lymph
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sentinel lymph node (SLN) surgery after neoadjuvant chemotherapy
Trial: 15197201
Drug: Fluorouracil-based combination
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil-based combination chemotherapy
Trial: 11473559
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg kg‐1 (group L)
Trial: 9710337
Drug: Intensive acupuncture
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive acupuncture (25 treatment sessions over 2 months, each lasting 30 minutes)
Trial: 25794439
Drug: Fortified yogurt
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fortified yogurt (FY; 2000 IU vitamin D in 100 g/day)
Trial: 17327864
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (5.9 g/day total n‐3 fatty acids; 1.8 g 20:5n‐3, 3.0 g 22:6n‐3)
Trial: 17327864
Drug: Corn oil
RxNorm normalized name: Corn Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn oil (8.5 g/day 18:2n‐6 FA)
Trial: 14653832
Drug: Intravenous pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pamidronate (30 mg) in combination with oral calcium (500 mg) and vitamin D (400 IU)
Trial: 14653832
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (500 mg) and vitamin D (400 IU) alone
Trial: 1354411
Drug: 0.1% ophthalmic
RxNorm normalized name: Vevye 0.1% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ophthalmic solution of 8-hydroxycarteolol
Trial: 1354411
Drug: 0.01%, 0.1%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01%, 0.1%, 0.5%, and 1% ophthalmic solutions of 8-hydroxycarteolol
Trial: 30583518
Drug: Navy bean
RxNorm normalized name: navy bean
DrugBank: Kidney bean (DB10639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navy bean consumption (35 g of cooked navy bean daily)
Trial: 30583518
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 g of navy beans)
Trial: 26323560
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg for 9 months
Trial: 20720255
Drug: Standardized meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized meal (providing 50% of the daily estimated energy requirements)
Trial: 2007100
Drug: Parascalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parascalene block with 0.5 ml/kg 0.25% bupivacaine with 1:200,000 epinephrine
Trial: 2007100
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (subcutaneous needle puncture only)
Trial: 7034757
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 1.5 ml in 8% glucose
Trial: 7034757
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 2 ml in 8% glucose
Trial: 7034757
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 3 ml in 8% glucose
Trial: 22810435
Drug: Cytokine levels
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokine levels (INF‐γ, TNF‐α, MIP‐1β, G‐CSF, MCP‐1β)
Trial: 15745927
Drug: hGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGH treatment (0.23 mg/kg per week)
Trial: 14608063
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid plus iron (60 mg)
Trial: 14608063
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid plus iron and zinc (30 mg)
Trial: 9201091
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg intravenously daily (N = 35)
Trial: 9201091
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg daily orally or by nasogastric route (N = 32)
Trial: 8382712
Drug: Intensified dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified dietary therapy (12 months of intensified education)
Trial: 8382712
Drug: Intensified dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensified dietary therapy
Trial: 8382712
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (visits to local health centers)
Trial: 3097701
Drug: Methylphenidate (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (active drug)
Trial: 30293597
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2000 mg)
Trial: 16140519
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine plus fentanyl (8 mL of 0.125% solution plus fentanyl 50 microg, maintained with 0.0625% solution with fentanyl 2 microg/mL)
Trial: 16140519
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine plus fentanyl (8 mL of 0.125% solution plus fentanyl 50 microg, maintained with 0.0625% solution with fentanyl 2 microg/mL)
Trial: 10072025
Drug: Propofol-thiopental combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-thiopental combination
Trial: 10072025
Drug: Midazolam-thiopental combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam-thiopental combination
Trial: 10072025
Drug: Propofol-midazolam combination
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-midazolam combination
Trial: 7482079
Drug: Surfactant replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant replacement therapy (SRT) at 3-4 hours after birth
Trial: 7482079
Drug: Surfactant replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant replacement therapy (SRT) at 6-8 hours after birth
Trial: 2345837
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (twice yearly)
Trial: 31518424
Drug: 25(OH)D3 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D3 (10 µg/d)
Trial: 31518424
Drug: 25(OH)D3 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D3 (15 µg/d)
Trial: 31518424
Drug: 25(OH)D3 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D3 (20 µg/d)
Trial: 31518424
Drug: D3 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 (20 µg/d)
Trial: 26432181
Drug: TEV-48125 675/225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEV-48125 675/225 mg
Trial: 26432181
Drug: TEV-48125 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEV-48125 900 mg
Trial: 24224471
Drug: anti-OX40L monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-OX40L monoclonal antibody (MAb)
Trial: 24224471
Drug: anti-OX40L monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-OX40L monoclonal antibody (MAb) and placebo
Trial: 17023874
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT) users
Trial: 17023874
Drug: Non-hormone therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-hormone therapy (non-HT) users
Trial: 10210789
Drug: Continuous monotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous monotherapy
Trial: 1983499
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy with clomethiazol and haloperidol (group 1)
Trial: 1983499
Drug: Continuous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous ethanol infusions (2‐4 g/h) postoperatively as prophylaxis for WS (group 2)
Trial: 7073790
Drug: Colestipol 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 0.125 g/kg body weight
Trial: 7073790
Drug: Colestipol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 0.25 g/kg body weight
Trial: 31311018
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion hemodiafiltration (I-HDF)
Trial: 25534747
Drug: Triflusal 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal 900 mg loading dose on Day 1, followed by 600 mg/day from Day 2 to 9
Trial: 21134450
Drug: Tdap (Boostrix®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi‐Pasteur) co-administered
Trial: 21134450
Drug: Tdap (Boostrix®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi‐Pasteur) administered sequentially one month apart
Trial: 19758646
Drug: 20 gm
RxNorm normalized name: HYQVIA 20 GM / 200 ML Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 gm soy protein containing 160 mg total isoflavones
Trial: 12510944
Drug: Ibuprofen (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (up to 1.2 g daily)
Trial: 12510944
Drug: Aspirin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (up to 3 g daily)
Trial: 12510944
Drug: Paracetamol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (up to 3 g daily)
Trial: 26892284
Drug: Post‐treatment infarct
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post‐treatment infarct volume
Trial: 7796057
Drug: 0.17-0.34- or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.17-0.34- or 0.51-M sucrose solution (2 ml)
Trial: 7796057
Drug: Water (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (2 ml)
Trial: 6963074
Drug: Intravenous PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous PGE2
Trial: 6963074
Drug: Intravenous sulprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous sulprostone (2 schedules)
Trial: 6963074
Drug: Intramuscular sulprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular sulprostone (2 schedules)
Trial: 30933354
Drug: First-line platinum-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line platinum-based chemotherapy (carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel)
Trial: 28053292
Drug: Polyphenon E®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenon E® (PolyE®) containing 200 mg EGCG administered with food, BID
Trial: 25056277
Drug: 11.25 mg
RxNorm normalized name: phentermine 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11.25 mg of 0.75% intrathecal hyperbaric bupivacaine
Trial: 25056277
Drug: 15.0 mg
RxNorm normalized name: RUXOLITINIB 15.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15.0 mg of 0.75% intrathecal hyperbaric bupivacaine
Trial: 31951273
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (casts)
Trial: 21752292
Drug: Aerosolized mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized mixed oil preparation (aloe, coconut, orange, peppermint, vitamin E)
Trial: 21752292
Drug: Aerosolized mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized mixed oil preparation
Trial: 14706058
Drug: Bedtime diazoxide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime diazoxide, 100 mg
Trial: 11034946
Drug: Cardiac troponin
RxNorm normalized name: Cardiac troponin I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac troponin T >0.10 ng/mL
Trial: 11034946
Drug: Baseline glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline glucose (1 mmol/L increase)
Trial: 11034946
Drug: Baseline triglycerides
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline triglycerides (1 mmol/L increase)
Trial: 8810610
Drug: TGF-beta release
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-beta release in BAL cell culture (n=12; 1,422 +/- 215 pg/ml; p < 0.004)
Trial: 8810610
Drug: TGF-beta release
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-beta release in BAL cell culture (n=21; 677 +/- 159 pg/ml)
Trial: 8810610
Drug: TGF-beta release
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-beta release in BAL cell culture (n=6; 762 +/- 419 pg/ml)
Trial: 8810610
Drug: TGF-beta release
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-beta release in BAL cell culture (n=5; 1,560 +/- 353 pg/ml)
Trial: 8810610
Drug: TGF-beta release
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-beta release in BAL cell culture (612 +/- 261.2 pg/ml)
Trial: 1565532
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate (EST) 40 mg/kg/day divided in 2 doses
Trial: 1565532
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (ETH) 60 mg/kg/day divided in 3 doses
Trial: 24456026
Drug: Sirolimus with
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus with reduced-dose tacrolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL; reduced-dose tacrolimus trough: 3-7 ng/mL)
Trial: 24456026
Drug: Sirolimus with
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus with reduced-dose tacrolimus
Trial: 24456026
Drug: Conventional-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose tacrolimus (trough: 7-15 ng/mL)
Trial: 24456026
Drug: Conventional-dose tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose tacrolimus
Trial: 19043140
Drug: Rosuvastatin and
RxNorm normalized name: rosuvastatin and ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin and Atorvastatin (comparison)
Trial: 19043140
Drug: Rosuvastatin and
RxNorm normalized name: rosuvastatin and ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin and Atorvastatin (absolute values)
Trial: 12725580
Drug: Ivy leaf
RxNorm normalized name: Ivy leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivy leaf extract syrup
Trial: 12725580
Drug: Ivy leaf
RxNorm normalized name: Ivy leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivy leaf extract suppositories
Trial: 3963154
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and scopolamine
Trial: 1915134
Drug: Scopolamine i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine i.v. (20 mg)
Trial: 1915134
Drug: Placebo i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo i.v. and scopolamine transdermally (0.5 mg)
Trial: 1915134
Drug: Transdermally applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermally applied scopolamine (0.5 mg)
Trial: 7041931
Drug: Phentolamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine 0.5 mg min‐1 infusion
Trial: 2414066
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation (buclizine 6.25 mg, codeine 8 mg, paracetamol 500 mg, with docusate sodium 10 mg)
Trial: 2414066
Drug: Combination without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination without docusate (buclizine 6.25 mg, codeine 8 mg, paracetamol 500 mg)
Trial: 2414066
Drug: Paracetamol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol alone (500 mg)
Trial: 27838646
Drug: Exenatide (17.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (17.4 μg over a 6-hour and 15-minute infusion)
Trial: 23980351
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (control group)
Trial: 14640996
Drug: Successful treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful treatment of hypercortisolism
Trial: 1505304
Drug: HUL/R (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HUL/R (twice-daily humulin ultralente insulin)
Trial: 6388585
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clotrimazole and hydrocortisone (Canesten HC)
Trial: 6388585
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clotrimazole and hydrocortisone
Trial: 21899733
Drug: Multi-nutrient supplement
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-nutrient supplement
Trial: 30771607
Drug: Childbirth preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Childbirth preparation course
Trial: 29391277
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi and Physical Therapy
Trial: 20515284
Drug: Biomarker testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biomarker testing (e.g., troponin)
Trial: 20515284
Drug: Therapeutic intervention
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic intervention (e.g., cardiac catheterization)
Trial: 18068058
Drug: Intrapleural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural analgesia with 20 mL of 0.5% bupivacaine every 6 hours for 4 days
Trial: 12011120
Drug: Azacitidine (Aza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (Aza C) 75 mg/m(2)/d subcutaneously for 7 days every 28 days
Trial: 9803110
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg SR orally immediately post-operatively)
Trial: 791332
Drug: Phentolamine (sustained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (sustained administration)
Trial: 791332
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxprenolol and phentolamine
Trial: 28921414
Drug: Multimedia diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimedia diabetes education program and nutrition therapy (NT + MDE)
Trial: 28921414
Drug: Nutrition therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition therapy only (NT)
Trial: 25695189
Drug: Ropivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine with 50 μg dexmedetomidine (RD50)
Trial: 25695189
Drug: Ropivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine with 100 μg dexmedetomidine (RD100)